Metformin is a metabolic modulator and radiosensitiser in rectal cancer

Resistance to neoadjuvant chemoradiation therapy, is a major challenge in the management of rectal cancer. Increasing evidence supports a role for altered energy metabolism in the resistance of tumours to anti-cancer therapy, suggesting that targeting tumour metabolism may have potential as a novel...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Croí E. Buckley, Rebecca M. O’Brien, Timothy S. Nugent, Noel E. Donlon, Fiona O’Connell, John V. Reynolds, Adnan Hafeez, Diarmuid S. O’Ríordáin, Robert A. Hannon, Paul Neary, Reza Kalbassi, Brian J. Mehigan, Paul H. McCormick, Cara Dunne, Michael E. Kelly, John O. Larkin, Jacintha O’Sullivan, Niamh Lynam-Lennon
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2023-08-01
سلاسل:	Frontiers in Oncology
الموضوعات:	metformin rectal cancer colorectal radiosensitiser energy metabolism radioresistance
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1216911/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!